The Diadenosine Homodinucleotide P18 Improves In Vitro Myelination in Experimental Charcot‐Marie‐Tooth Type 1A

Nobbio, Lucilla; Visigalli, Davide; Mannino, Elena; Fiorese, Fulvia; Kassack, Matthias U.; Sturla, Laura; Prada, Valeria; Flora, Antonio De; Zocchi, Elena; Bruzzone, Santina; Schenone, Angelo

doi:10.1002/jcb.24644

Cited by 9 publications

(10 citation statements)

References 50 publications

(82 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This cannot be considered valid proof of P2Y 11 receptor activation, since ATP might also act through P2Y 2 to stimulate cellular release of arachidonic acid, which can act in an autocrine fashion after conversion to prostaglandins and result in a rise in intracellular cAMP through prostaglandin receptors [85]. This is also evidenced by the observation that stimulation with ATP results in significant cAMP increases in various cell types in rats and mice [11][12][13][14][15][16]86]. This shows that the mechanism for an increase in intracellular cAMP following ATP stimulation is not by itself proof of P2Y 11 receptor activation.…”

Section: Selective P2y 11 Activation and Inhibitionmentioning

confidence: 99%

“…This strongly suggests that the murine genomes do not encode a genuine P2ry11 gene. Stimulation of murine cells with ATP has been shown to increase cyclic adenosine 3′,5′-monophosphate (cAMP), a phenomenon attributed to P2Y 11 in human cells [11][12][13][14][15][16]. The rise in cAMP could arise from secondary effects of ATP acting through other signalling pathways, and the existence of an as yet uncharacterized adenylyl cyclase-coupled receptor sensing ATP cannot be excluded.…”

Section: Nonexistence Of a Murine P2ry11 Gene Orthologuementioning

confidence: 99%

“…One example is that of the diadenosine diphosphate isomer P18, which both antagonizes P2X7 and activates P2Y 11 [14,81], demonstrating the need to test possible P2Y 11 agonistic and antagonistic compounds on all ATPbinding P2 receptors before drawing any conclusions about specificity.…”

Section: Selective P2y 11 Activation and Inhibitionmentioning

confidence: 99%

“…It is also worth noting that NF157, NF340, and NF546 have all been used to study the murine BP2Y 11 -like receptort hat shows many of the same properties as seen in humans [14,[41][42][43][82][83][84]. Assuming that no P2Y 11 receptor exists in murines, these compounds must have other mechanisms by which they interfere with cell signalling.…”

Section: Selective P2y 11 Activation and Inhibitionmentioning

confidence: 99%

See 3 more Smart Citations

A critical look at the function of the P2Y11 receptor

Dreisig

Kornum

2016

Purinergic Signalling

View full text Add to dashboard Cite

The P2Y 11 receptor is a member of the purinergic receptor family. It has been overlooked, somewhat due to the lack of a P2ry11 gene orthologue in the murine genome, which prevents the generation of knockout mice, which have been so helpful for defining the roles of other P2Y receptors. Furthermore, some of the studies reported to date have methodological shortcomings, making it difficult to determine the function of P2Y 11 with certainty. In this review, we discuss the lack of a murine BP2Y 11 -like receptor^and highlight the limitations of the currently available methods used to investigate the P2Y 11 receptor. These methods include protein recognition with antibodies that show very little specificity, gene expression studies that completely overlook the existence of a fusion transcript between the adjacent PPAN gene and P2RY11, and agonists/antagonists reported to be specific for the P2Y 11 receptor but which have not been tested for activity on numerous other adenosine 5′-triphosphate (ATP)-binding receptors. We suggest a set of criteria for evaluating whether a dataset describes effects mediated by the P2Y 11 receptor. Following these criteria, we conclude that the current evidence suggests a role for P2Y 11 in immune activation with cell typespecific effects.

show abstract

Section: Selective P2y 11 Activation and Inhibitionmentioning

confidence: 99%

Section: Nonexistence Of a Murine P2ry11 Gene Orthologuementioning

confidence: 99%

Section: Selective P2y 11 Activation and Inhibitionmentioning

confidence: 99%

Section: Selective P2y 11 Activation and Inhibitionmentioning

confidence: 99%

See 2 more Smart Citations

A critical look at the function of the P2Y11 receptor

Dreisig

Kornum

2016

Purinergic Signalling

View full text Add to dashboard Cite

show abstract

“…These studies are mostly in animal models or cultured tissues. The initiating step in all of the above mechanism is a PMP22 toxic gain of function [18][19][20][21]25,27,33,47,49,51,52,65,67]. …”

Section: Diagnostic Featuresmentioning

confidence: 99%

Molecular and clinical features of inherited neuropathies due to PMP22 duplication

Watila

Balarabe²

2015

Journal of the Neurological Sciences

View full text Add to dashboard Cite

Purinergic signaling in peripheral nervous system glial cells

Cram

Coover

Jankowski

et al. 2021

Glia

View full text Add to dashboard Cite

To facilitate analyses of purinergic signaling in peripheral nerve glia, we review recent literature and catalog purinergic receptor mRNA expression in cultured mouse Schwann cells (SCs). Purinergic signaling can decrease developmental SC proliferation, and promote SC differentiation. The purinergic receptors P2RY2 and P2RX7 are implicated in nerve development and in the ratio of Remak SCs to myelinating SCs in differentiated peripheral nerve. P2RY2, P2RX7, and other receptors are also implicated in peripheral neuropathies and SC tumors. In SC tumors lacking the tumor suppressor NF1, the SC pathway that suppresses SC growth through P2RY2‐driven β‐arrestin‐mediated AKT signaling is aberrant. SC‐released purinergic agonists acting through SC and/or neuronal purinergic receptors activate pain responses. In all these settings, purinergic receptor activation can result in calcium‐independent and calcium‐dependent release of SC ATP and UDP, growth factors, and cytokines that may contribute to disease and nerve repair. Thus, current research suggests that purinergic agonists and/or antagonists might have the potential to modulate peripheral glia function in development and in disease.

show abstract

The Diadenosine Homodinucleotide P18 Improves In Vitro Myelination in Experimental Charcot‐Marie‐Tooth Type 1A

Abstract: ABSTRACT

Cited by 9 publications

References 50 publications

A critical look at the function of the P2Y11 receptor

A critical look at the function of the P2Y11 receptor

Molecular and clinical features of inherited neuropathies due to PMP22 duplication

Purinergic signaling in peripheral nervous system glial cells

Contact Info

Product

Resources

About